GLP-1 Analogues Market

GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2032

Report Code: PH 9080 Jul, 2024, by marketsandmarkets.com

GLP-1 Analogues Market Size, Share & Trends

The size of global GLP-1 analogues market in terms of revenue was estimated to be worth $47.4 billion in 2024 and is poised to reach $471.1 billion by 2029, growing at a CAGR of 33.2% from 2024 to 2032. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.

GLP-1 analogue drugs have gained high acceptance in recent years, especially after their benefits in treating chronic obesity and weight management became known widely. In addition, the clinical pipeline for this drug class is strong. The pipeline reveals an abundance of products (existing and innovative molecules) expected to launch during the forecast period. A few notable product instances include- Oral semaglutide (25 mg and 50 mg) for type 2 diabetes, CagriSema (a combination product of Cagrilintide and Semaglutide) for obesity as well as type 2 diabetes, Survodutide for the treatment of obesity and Nonalcoholic steatohepatitis (NASH), Semaglutide against NASH, and among others. Thus, this is a key factor driving market growth. However, more than 90% of the marketed products are offered by two key players in the market- Novo Nordisk A/S and Eli Lilly and Company. This has created a duopoly in the market. This factor thus, is expected to create high entry barriers for new entrants in the market.

GLP-1 Analogues Market Trends

GLP-1 Analogues Market

To know about the assumptions considered for the study, Request for Free Sample Report

GLP-1 Analogues Market

GLP-1 Analogues Market Dynamics

Driver: Strong R&D pipeline

GLP-1 analogues is a class of drugs referred to as incretin mimetics. These drugs aid in regulating blood glucose levels and promote satiety thus, used in the treatment of diabetes and obesity. The drugs have been in high demand for treating obesity in recent years. Also, the drug class is highly adopted for the treatment of type 2 diabetes. Therefore, many key players are in the development of novel drugs for this class. The clinical pipeline reflects a wide range of products in development, along with existing products being tested for novel indications such as Nonalcoholic Steatohhepatitis (NASH) and Alzheimer’s disease, among others. The R&D pipeline is dominated by Novo Nordisk A/S which is the leading player in this market along with some other large pharmaceutical and biopharmaceutical companies like Boehringer Ingelheim International GmbH (Survodutide), Eli Lilly and Company (Retatrutide, Orforglipron), Innovent (IBI362/Mazdutide), Hanmi Pharm (partnered with Merck; Efinopegdutide), Zealand Pharma A/S (Dapiglutide), and Pfizer, Inc. (Danuglipron), among others. Some of the key products of focus include combination products like CagriSema (combination of Cagrilintide and semaglutide) and IcoSema (combination of basal insulin icodec and semaglutide), and oral GLP-1 products.

Restraint: High entry barriers due to duopoly

The market is dominated by two players- Novo Nordisk A/S (Denmark) and Eli Lilly and Company (US). These key players form a duopoly in the market for currently marketed GLP-1 analogues. Some of the key attributes of this duopoly include- strong brand recognition of the products, established geographic network through which the companies offer their GLP-1 analogues globally, and developed and established infrastructure that supports supply to meet the high demand for GLP-1 analogue drugs. Moreover, both companies have patented formulations that restrict generic drug makers from entering this space. Additionally, anticipating high demand for this GLP-1 analogues, the companies are further developing novel therapeutics of this drug class and also enhancing existing manufacturing capacity.

Opportunity: Extended therapeutic uses

The GLP-1 analogues have been traditionally used for the treatment of diabetes as they regulate blood glucose level. Additionally, with the observation of features such as providing enhanced satiety and slower gastric emptying, they have also been highly adopted for the treatment of obesity. The GLP-1 analogues drugs class is now being studied for its potential in the treatment of other indications such as NASH (nonalcoholic steatohepatitis), Alzheimer’s disease, Obstructive Sleep Apnea (OSA) and several cardiovascular indications. GLP-1 analogues help manage weight loss which is a key factor in managing NASH. Moreover, they have shown potential neuroprotective effects, and they possess anti-inflammatory properties that aid in mitigating the chronic inflammation associated with Alzheimer’s disease. Such factors are expected to support adoption of GLP-1 analogues for a wide range of indications.

Challenge: Non-adherence to therapy after 12-24 months

The GLP-1 analogues is a drug class that has gained high adoption for the treatment of type 2 diabetes and obesity. Treatment adherence is the patient’s actions aligning with the prescribed therapeutic regimen. Thus, non-adherence refers to stopping medications before the complete treatment duration is passed, irregular consumption of doses, and not consuming medication as directed. Patients on GLP-1 analogues have been observed not adhering to the treatment post 12 months of initiation. For instance, a study of antiobesity GLP-1 drugs- Wegovy and Saxenda, reveals a drop to 32% of patients remaining on treatment by end 12 months since initiation of the treatment for Wegovy. This share is 21% for Saxenda. A few reasons noted for the same include the injectable nature of the majority of products, side effects such as nausea and vomiting, and high prices in developing economies. Disease bias or stigma, supply constraints and access to these medicinecs are few of the key reasons for patients quitting anti-obesity GLP-1s. Thus, the growing development of oral GLP-1 analogues with minimal side effects is expected to reduce the impact of this challenge.

GLP-1 analogues Market Ecosystem

Prominent companies in the market include companies that have been operating for several years and possess a diversified product portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in the market include Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), and AstraZeneca (UK), among others.

Ecosystem analysis

The GLP-1 analogues market ecosystem comprises supply-side companies as well as demand-side entities that significantly contribute to market growth. The supply-side ecosystem includes pharmaceutical and biotechnology companies, while demand-side entities include home care settings, long-term care facilities, hospitals, and specialty clinics.

GLP-1 Analogues Market Ecosystem

Ozempic accounted for the largest share of the product segment in overall GLP-1 analogues industry in 2023.

On the basis of product, the GLP-1 analogues market is segmented product into Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Xultophy, Soliqua, Zepbound, Bydureon, and other products. In 2023, the Ozempic segment accounted for the largest share of the market owing to factors such as strong brand recognition for the product, and an established geographic availability globally support the growth of this segment.

The single dose segment dominates the format segment in overall GLP-1 analogues industry in 2023.

On the basis of format, the GLP-1 analogues market is segmented into single-dose, multi-dose, and tablets. Single dose accounted for the largest share of the market owing to factors like the ease of administration offered by single dose formulations. Additionally, the availability of the products in autoinjector format further eases the self-administration process. Moreover, single dose format are administered once weekly leading to higher adherence.

North America was the largest market for overall GLP-1 analogues industry in 2023 and also during the forecast period.

Geographically, the GLP-1 analogues market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The market was dominated by North America in 2023 and this dominance is anticipated to continue throughout the forecast period between 2024 and 2032. The market for GLP-1 analogues is expanding in the North America region as a result of factors like availability and access to majority of the GLP-1 analogue products and high demand for these drugs in the region for indications including type 2 diabetes and obesity.

GLP-1 Analogues Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the GLP-1 analogues market are Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), and AstraZeneca (UK) among others.

Scope of the GLP-1 Analogues Industry

Report Metric

Details

Market Revenue in 2024

$47.4 billion

Projected Revenue by 2032

$471.1 billion

Revenue Rate

Poised to Grow at a CAGR of 33.2%

Market Driver

Strong R&D pipeline

Market Opportunity

Extended therapeutic uses

All the market segments have been divided for the GLP-1 Analogues market to forecast revenue and analyze trends in each of the following submarkets:

By Product
  • Ozempic
  • Wegovy
  • Rybelsus
  • Saxenda
  • Victoza
  • Trulicity
  • Mounjaro
  • Zepbound
  • Soliqua
  • Xultophy
  • Bydureon
  • Other products
By Format
  • Single-dose
  • Multi-dose
  • Tablets
By Route of Administration
  • Subcutaneous
    • Pen injector
    • Autoinjector
  • Oral
By Indication
  • Diabetes
  • Obesity
  • Other indications
By End User
  • Hospitals and specialty clinics
  • Long-term care facilities
  • Home care settings
By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Netherlands
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East
    • GCC
      • Saudi arabia (ksa)
      • United arab emirates (uae)
      • Rest of GCC
    • Rest of Middle East
  • Africa

Recent Developments of GLP-1 Analogues Industry:

  • In March 2024, the US FDA approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for reducing risks of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attack (myocardial infarction) or non-fatal stroke in adults with either overweight or obesity and established CVD.
  • In November 2023, Eli Lilly and Company (US) received US FDA approval for Zepbound, an obesity treatment that activates GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 29)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
                    FIGURE 1 GLP-1 ANALOGUES MARKET SEGMENTATION
           1.3.2 REGIONS COVERED
                    FIGURE 2 GLP-1 ANALOGUES INDUSTRY: REGIONAL SEGMENTATION
           1.3.3 YEARS CONSIDERED
           1.3.4 CURRENCY CONSIDERED
    1.4 STAKEHOLDERS 
    1.5 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 33)
    2.1 RESEARCH DATA 
          FIGURE 3 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 5 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
          FIGURE 6 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
          FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
           2.2.1 MARKET SIZE ASSESSMENT
                    FIGURE 8 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
    2.3 MARKET GROWTH FORECAST 
          FIGURE 9 CAGR PROJECTIONS: GLP-1 ANALOGUES MARKET, 2024–2032
          FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN GLP-1 ANALOGUES INDUSTRY
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION 
          FIGURE 11 DATA TRIANGULATION METHODOLOGY
    2.5 STUDY ASSUMPTIONS 
    2.6 LIMITATIONS 
    2.7 RISK ANALYSIS 
    2.8 RECESSION IMPACT ANALYSIS 
          TABLE 1 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 44)
    FIGURE 12 GLP-1 ANALOGUES MARKET, BY PRODUCT, 2024 VS. 2032 (USD BILLION)
    FIGURE 13 GLP-1 ANALOGUES INDUSTRY SHARE, BY FORMAT, 2024 VS. 2032 (USD BILLION)
    FIGURE 14 MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2024 VS. 2032 (USD BILLION)
    FIGURE 15 MARKET SHARE, BY INDICATION, 2024 VS. 2032 (USD BILLION)
    FIGURE 16 MARKET, BY END USER, 2024−2032 (USD BILLION)
    FIGURE 17 MARKET: GEOGRAPHICAL SNAPSHOT
 
4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 GLP-1 ANALOGUES MARKET OVERVIEW 
          FIGURE 18 IMPROVED EFFICACY OF GLP-1 DRUGS TO DRIVE MARKET GROWTH
    4.2 NORTH AMERICA: GLP-1 ANALOGUES INDUSTRY SHARE, BY INDICATION AND COUNTRY (2023) 
          FIGURE 19 DIABETES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
    4.3 MARKET SHARE, BY PRODUCT, 2024 VS. 2032 
          FIGURE 20 OZEMPIC TO DOMINATE MARKET IN 2032
    4.4 MARKET SHARE, BY INDICATION, 2023 
          FIGURE 21 DIABETES INDICATIONS TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023
    4.5 MARKET SHARE, BY END USER, 2024 VS. 2032 
          FIGURE 22 HOME CARE SETTINGS TO DOMINATE THE MARKET IN 2032
    4.6 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 23 US TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 53)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 24 GLP-1 ANALOGUES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 2 GLP-1 ANALOGUES INDUSTRY: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Strong R&D pipeline
                    5.2.1.2 Improved relative efficacy of GLP-1 drugs
                    5.2.1.3 High demand, expanding insurance coverage, growing sales, increasing awareness, and positive outcomes
           5.2.2 RESTRAINTS
                    5.2.2.1 High barriers for new entrants due to duopoly
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Extended therapeutic uses
                                FIGURE 25 US: PREVALENCE OF INDICATIONS THAT MAY RESPOND TO GLP-1 DRUGS (AS OF JANUARY 2024)
                    5.2.3.2 Integration of GLP-1 drugs into telehealth and digital weight management programs
           5.2.4 CHALLENGES
                    5.2.4.1 Off-label use of GLP-1 drugs
                    5.2.4.2 High non-adherence to therapy after 12–24 months
    5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 26 REVENUE SHIFT IN MARKET
    5.4 PRICING ANALYSIS 
           5.4.1 AVERAGE SELLING PRICE TREND OF GLP-1 ANALOGUES
                    FIGURE 27 AVERAGE SELLING PRICE TREND, BY PRODUCT
           5.4.2 AVERAGE SELLING PRICES OF TOP GLP-1 ANALOGUES, BY COUNTRY/REGION
                    TABLE 3 AVERAGE SELLING PRICE RANGE OF TOP GLP-1 ANALOGUES (2023–2024)
                    FIGURE 28 PRODUCT PRICING, BY COUNTRY (2023–2024)
    5.5 TECHNOLOGY ANALYSIS 
           5.5.1 KEY TECHNOLOGIES
                    5.5.1.1 Chemical Synthesis
                    5.5.1.2 Recombinant DNA Technology
           5.5.2 ADJACENT TECHNOLOGIES
                    5.5.2.1 Hydrogel Depot Technology
                    5.5.2.2 Technologies for oral delivery of GLP-1 analogues
    5.6 PIPELINE ANALYSIS 
          TABLE 4 GLP-1 ANALOGUES IN CLINICAL PIPELINE (AS OF MAY 2024)
          FIGURE 29 ADDITIONAL LAUNCHES OF GLP-1 DRUGS, 2025–2032
          FIGURE 30 PHASE 3 PIPELINE, BY INDICATION
    5.7 TRADE DATA 
    5.8 PATENT ANALYSIS 
           5.8.1 METHODOLOGY
           5.8.2 INNOVATION AND PATENT APPLICATIONS
                    FIGURE 31 TOTAL NUMBER OF PATENTS GRANTED, 2014–2024
           5.8.3 TOP APPLICANTS
                    FIGURE 32 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2024
                    TABLE 5 TOP 20 PATENT OWNERS IN MARKET, 2014–2024
                    TABLE 6 INDICATIVE LIST OF PATENTS IN MARKET, 2022–2024
    5.9 VALUE CHAIN ANALYSIS 
          FIGURE 33 VALUE CHAIN ANALYSIS: PRODUCT DEVELOPMENT AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE
    5.10 SUPPLY CHAIN ANALYSIS 
           FIGURE 34 MARKET: SUPPLY CHAIN ANALYSIS
    5.11 ECOSYSTEM ANALYSIS 
           FIGURE 35 MARKET: ECOSYSTEM ANALYSIS
           5.11.1 MARKET: ROLE OF RAW MATERIAL VENDORS
                     TABLE 7 MARKET: ROLE OF RAW MATERIAL VENDORS
           5.11.2 MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE 3 PIPELINE PRODUCT COMPANIES
                     TABLE 8 MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE 3 PIPELINE PRODUCT COMPANIES
           5.11.3 MARKET: ROLE OF END USERS
                     TABLE 9 MARKET: ROLE OF END USERS
           5.11.4 MARKET: ROLE OF REGULATORY AUTHORITIES
                     TABLE 10 MARKET: ROLE OF REGULATORY AUTHORITIES
    5.12 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 11 MARKET: PORTER’S FIVE FORCES ANALYSIS
           FIGURE 36 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.12.1 THREAT OF NEW ENTRANTS
           5.12.2 THREAT OF SUBSTITUTES
           5.12.3 BARGAINING POWER OF SUPPLIERS
           5.12.4 BARGAINING POWER OF BUYERS
           5.12.5 INTENSITY OF COMPETITIVE RIVALRY
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 37 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GLP-1 ANALOGUES, HOSPITALS
           5.13.2 BUYING CRITERIA FOR GLP-1 ANALOGUES
                     FIGURE 38 KEY BUYING CRITERIA FOR END USERS
                     TABLE 12 BUYING CRITERIA FOR GLP-1 ANALOGUES, BY END USER
    5.14 REGULATORY LANDSCAPE 
           5.14.1 REGULATORY SCENARIO
           5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    5.14.2.1 North America
                                 TABLE 13 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    5.14.2.2 Europe
                                 TABLE 14 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    5.14.2.3 Asia Pacific
                                 TABLE 15 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    5.14.2.4 Rest of the World
                                 TABLE 16 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.15 KEY CONFERENCES & EVENTS, 2024–2025 
           TABLE 17 MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2024–2025
    5.16 CASE STUDIES 
           5.16.1 STUDY OF TIRZEPATIDE AS A CASE IN GLP-1 DRUGS MARKET
           5.16.2 OZEMPIC OFF-LABEL USE
    5.17 INVESTMENT AND FUNDING SCENARIO 
 
6 GLP-1 ANALOGUES MARKET, BY PRODUCT (Page No. - 91)
    6.1 INTRODUCTIONS 
          TABLE 18 GLP-1 ANALOGUES INDUSTRY, BY PRODUCT, 2022–2032 (USD BILLION)
          TABLE 19 MARKET FOR ANTI-OBESITY PRODUCTS (MILLION UNITS)
    6.2 OZEMPIC 
           6.2.1 RISING ADOPTION TO SUPPORT MARKET GROWTH
                    TABLE 20 OZEMPIC MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 21 NORTH AMERICA: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 22 EUROPE: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 23 ASIA PACIFIC: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 24 LATIN AMERICA: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 25 MIDDLE EAST: OZEMPIC MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 26 GCC COUNTRIES: OZEMPIC MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
    6.3 TRULICITY 
           6.3.1 COMPETITOR REVENUE GROWTH TO AFFECT GROWTH
                    TABLE 27 TRULICITY MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 28 NORTH AMERICA: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 29 EUROPE: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 30 ASIA PACIFIC: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 31 LATIN AMERICA: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 32 MIDDLE EAST: TRULICITY MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 33 GCC COUNTRIES: TRULICITY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
    6.4 MOUNJARO 
           6.4.1 EXPONENTIAL GROWTH ANTICIPATED DUE TO HIGH ADOPTION IN NORTH AMERICA
                    TABLE 34 MOUNJARO MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 35 NORTH AMERICA: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 36 EUROPE: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 37 ASIA PACIFIC: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 38 LATIN AMERICA: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 39 MIDDLE EAST: MOUNJARO MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 40 GCC COUNTRIES: MOUNJARO MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
    6.5 WEGOVY 
           6.5.1 INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT GROWTH
                    TABLE 41 WEGOVY MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 42 NORTH AMERICA: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 43 EUROPE: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 44 ASIA PACIFIC: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 45 LATIN AMERICA: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 46 MIDDLE EAST: WEGOVY MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 47 GCC COUNTRIES: WEGOVY MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
    6.6 RYBELSUS 
           6.6.1 CONVENIENCE OF ORAL ADMINISTRATION TO DRIVE MARKET
                    TABLE 48 RYBELSUS MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 49 NORTH AMERICA: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 50 EUROPE: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 51 ASIA PACIFIC: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 52 LATIN AMERICA: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 53 MIDDLE EAST: RYBELSUS MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 54 GCC COUNTRIES: RYBELSUS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
    6.7 SAXENDA 
           6.7.1 DEVELOPMENT OF GENERIC VERSIONS TO SLOW GROWTH
                    TABLE 55 SAXENDA MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 56 NORTH AMERICA: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 57 EUROPE: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 58 ASIA PACIFIC: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 59 LATIN AMERICA: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 60 MIDDLE EAST: SAXENDA MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 61 GCC COUNTRIES: SAXENDA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
    6.8 VICTOZA 
           6.8.1 ADOPTION OF ORAL GLP-1S TO RESTRAIN MARKET GROWTH
                    TABLE 62 VICTOZA MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 63 NORTH AMERICA: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 64 EUROPE: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 65 ASIA PACIFIC: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 66 LATIN AMERICA: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 67 MIDDLE EAST: VICTOZA MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 68 GCC COUNTRIES: VICTOZA MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
    6.9 XULTOPHY 
           6.9.1 REGULATORY APPROVALS TO SUPPORT MARKET GROWTH
                    TABLE 69 XULTOPHY MARKET, BY REGION, 2022–2032 (USD BILLION)
    6.10 SOLIQUA 
           6.10.1 COMPETITOR GLP-1 PRODUCTS THREAT TO GROWTH
                     TABLE 70 SOLIQUA MARKET, BY REGION, 2022–2032 (USD BILLION)
    6.11 ZEPBOUND 
           6.11.1 STRONG REVENUE GROWTH TO ENSURE CONTINUED PRESENCE
                     TABLE 71 ZEPBOUND MARKET, BY REGION, 2022–2032 (USD BILLION)
                     TABLE 72 NORTH AMERICA: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                     TABLE 73 EUROPE: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                     TABLE 74 ASIA PACIFIC: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                     TABLE 75 LATIN AMERICA: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                     TABLE 76 MIDDLE EAST: ZEPBOUND MARKET, BY REGION, 2022–2032 (USD BILLION)
                     TABLE 77 GCC COUNTRIES: ZEPBOUND MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
    6.12 BYDUREON 
           6.12.1 COMPETITOR PRODUCTS TO AFFECT MARKET GROWTH
                     TABLE 78 BYDUREON MARKET, BY REGION, 2022–2032 (USD BILLION)
    6.13 OTHER PRODUCTS 
           TABLE 79 OTHER PRODUCTS MARKET, BY REGION, 2022–2032 (USD BILLION)
 
7 GLP-1 ANALOGUES MARKET, BY FORMAT (Page No. - 118)
    7.1 INTRODUCTIONS 
          TABLE 80 GLP-1 ANALOGUES INDUSTRY, BY FORMAT, 2022–2032 (USD BILLION)
    7.2 SINGLE DOSE GLP-1 ANALOGUES
           7.2.1 HIGH ADOPTION DUE TO EASE OF ADMINISTRATION TO SUPPORT GROWTH
                    TABLE 81 MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 82 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 83 EUROPE: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 84 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 85 LATIN AMERICA: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 86 MIDDLE EAST: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 87 GCC COUNTRIES: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
    7.3 MULTI-DOSE GLP-1 ANALOGUES
           7.3.1 LOW COST TO ATTRACT LARGER ADOPTION
                    TABLE 88 MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 89 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 90 EUROPE: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 91 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 92 LATIN AMERICA: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 93 MIDDLE EAST: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 94 GCC COUNTRIES: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
    7.4 TABLETS 
           7.4.1 DEVELOPMENT OF HIGH-POTENCY GLP-1S TO SUPPORT MARKET GROWTH
                    TABLE 95 GLP-1 ANALOGUE TABLETS MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 96 NORTH AMERICA: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 97 EUROPE: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 98 ASIA PACIFIC: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 99 LATIN AMERICA: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 100 MIDDLE EAST: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 101 GCC COUNTRIES: GLP-1 ANALOGUE TABLETS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
 
8 GLP-1 ANALOGUES MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 128)
    8.1 INTRODUCTION 
          TABLE 102 GLP-1 ANALOGUES INDUSTRY, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
    8.2 SUBCUTANEOUS ADMINISTRATION GLP-1 ANALOGUES
          TABLE 103 MARKET, BY TYPE, 2022–2032 (USD BILLION)
          TABLE 104 MARKET, BY REGION, 2022–2032 (USD BILLION)
          TABLE 105 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2032 (USD MILLION)
          TABLE 106 EUROPE: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
          TABLE 107 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
          TABLE 108 LATIN AMERICA: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
          TABLE 109 MIDDLE EAST: MARKET, BY REGION, 2022–2032 (USD BILLION)
          TABLE 110 GCC COUNTRIES: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
           8.2.1 PEN INJECTORS
                    8.2.1.1 Ease of monitoring to support adoption
                                TABLE 111 GLP-1 ANALOGUE PEN INJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
                                TABLE 112 NORTH AMERICA: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                                TABLE 113 EUROPE: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                                TABLE 114 ASIA PACIFIC: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                                TABLE 115 LATIN AMERICA: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                                TABLE 116 MIDDLE EAST: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
                                TABLE 117 GCC COUNTRIES: GLP-1 ANALOGUE PEN INJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
           8.2.2 AUTOINJECTORS
                    8.2.2.1 Advantages offered over pen injectors to support adoption
                                TABLE 118 GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
                                TABLE 119 NORTH AMERICA: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                                TABLE 120 EUROPE: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                                TABLE 121 ASIA PACIFIC: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                                TABLE 122 LATIN AMERICA: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                                TABLE 123 MIDDLE EAST: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY REGION, 2022–2032 (USD BILLION)
                                TABLE 124 GCC COUNTRIES: GLP-1 ANALOGUE AUTOINJECTORS MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
    8.3 ORAL ADMINISTRATION GLP-1 ANALOGUES
           8.3.1 ELIMINATION OF NEEDLE PHOBIA AND EASE OF USE TO DRIVE COMPLIANCE
                    TABLE 125 MARKET, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 126 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 127 EUROPE: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 128 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 129 LATIN AMERICA: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 130 MIDDLE EAST: MARKET, BY REGION, 2022–2032 (USD MILLION)
                    TABLE 131 GCC COUNTRIES: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
 
9 GLP-1 ANALOGUES MARKET, BY INDICATION (Page No. - 142)
    9.1 INTRODUCTION 
          TABLE 132 GLP-1 ANALOGUES INDUSTRY, BY INDICATION, 2022–2032 (USD BILLION)
    9.2 DIABETES 
           9.2.1 HIGH EFFICACY TO SUPPORT MARKET GROWTH
                    TABLE 133 MARKET FOR DIABETES, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 134 NORTH AMERICA: MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 135 EUROPE: MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 136 ASIA PACIFIC: MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 137 LATIN AMERICA: MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 138 MIDDLE EAST: MARKET FOR DIABETES, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 139 GCC COUNTRIES: MARKET FOR DIABETES, BY COUNTRY, 2022–2032 (USD BILLION)
    9.3 OBESITY 
           9.3.1 INCREASING DEMAND AND PIPELINE FOCUS ON ANTI-OBESITY GLP-1S TO DRIVE MARKET
                    TABLE 140 MARKET FOR OBESITY, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 141 NORTH AMERICA: MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 142 EUROPE: MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 143 ASIA PACIFIC: MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 144 LATIN AMERICA: MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
                    TABLE 145 MIDDLE EAST: MARKET FOR OBESITY, BY REGION, 2022–2032 (USD BILLION)
                    TABLE 146 GCC COUNTRIES: MARKET FOR OBESITY, BY COUNTRY, 2022–2032 (USD BILLION)
    9.4 OTHER INDICATIONS 
          TABLE 147 MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2032 (USD BILLION)
          TABLE 148 NORTH AMERICA: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
          TABLE 149 EUROPE: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
          TABLE 150 ASIA PACIFIC: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
          TABLE 151 LATIN AMERICA: MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD BILLION)
          TABLE 152 MIDDLE EAST: MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2032 (USD BILLION)
 
10 GLP-1 ANALOGUES MARKET, BY END USER (Page No. - 152)
     10.1 INTRODUCTIONS 
             TABLE 153 GLP-1 ANALOGUES INDUSTRY, BY END USER, 2022–2032 (USD BILLION)
     10.2 HOME CARE SETTINGS 
             10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
                        TABLE 154 MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2032 (USD BILLION)
                        TABLE 155 NORTH AMERICA: FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
                        TABLE 156 EUROPE: MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
                        TABLE 157 ASIA PACIFIC: MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
                        TABLE 158 LATIN AMERICA: MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
                        TABLE 159 MIDDLE EAST: MARKET FOR HOME CARE SETTINGS, BY REGION, 2022–2032 (USD BILLION)
                        TABLE 160 GCC COUNTRIES: MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2032 (USD BILLION)
     10.3 LONG-TERM CARE FACILITIES 
             10.3.1 GROWING GERIATRIC POPULATION AND RISING CHRONIC DISEASE INCIDENCE TO DRIVE MARKET
                        TABLE 161 MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2032 (USD BILLION)
                        TABLE 162 NORTH AMERICA: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
                        TABLE 163 EUROPE: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
                        TABLE 164 ASIA PACIFIC: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
                        TABLE 165 LATIN AMERICA: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
                        TABLE 166 MIDDLE EAST: MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2032 (USD BILLION)
                        TABLE 167 GCC COUNTRIES: MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2032 (USD BILLION)
     10.4 HOSPITALS & SPECIALTY CLINICS 
             10.4.1 ADOPTION OF GLP-1 FOR VARIED INDICATIONS TO SUPPORT MARKET GROWTH
                        TABLE 168 MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2032 (USD BILLION)
                        TABLE 169 NORTH AMERICA: MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
                        TABLE 170 EUROPE: MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
                        TABLE 171 ASIA PACIFIC: MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
                        TABLE 172 LATIN AMERICA: MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
                        TABLE 173 MIDDLE EAST: MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022–2032 (USD BILLION)
                        TABLE 174 GCC COUNTRIES: MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2022–2032 (USD BILLION)
 
11 GLP-1 ANALOGUES MARKET, BY REGION (Page No. - 163)
     11.1 INTRODUCTION 
             TABLE 175 GLP-1 ANALOGUES INDUSTRY, BY REGION, 2022–2032 (USD BILLION)
     11.2 NORTH AMERICA 
             11.2.1 NORTH AMERICA: RECESSION IMPACT
                        FIGURE 39 NORTH AMERICA GLP-1 ANALOGUES MARKET SNAPSHOT
                        TABLE 176 NORTH AMERICA: MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                        TABLE 177 NORTH AMERICA: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                        TABLE 178 NORTH AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                        TABLE 179 NORTH AMERICA: MARKET, BY TYPE, 2022–2032 (USD BILLION)
                        TABLE 180 NORTH AMERICA: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                        TABLE 181 NORTH AMERICA: MARKET, BY END USER, 2022–2032 (USD BILLION)
                        TABLE 182 NORTH AMERICA: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
             11.2.2 US
                        11.2.2.1 Strategic developments by major players and R&D activities to drive market
                                      TABLE 183 US: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 184 US: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 185 US: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 186 US: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 187 US: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 188 US: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.2.3 CANADA
                        11.2.3.1 Strong research infrastructure and availability of funding to support market growth
                                      TABLE 189 CANADA: MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 190 CANADA: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 191 CANADA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 192 CANADA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 193 CANADA: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 194 CANADA: MARKET, BY END USER, 2022–2032 (USD BILLION)
     11.3 EUROPE 
             11.3.1 EUROPE: RECESSION IMPACT
                        FIGURE 40 EUROPE: GLP-1 ANALOGUES MARKET SNAPSHOT
                        TABLE 195 EUROPE: MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                        TABLE 196 EUROPE: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                        TABLE 197 EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                        TABLE 198 EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                        TABLE 199 EUROPE: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                        TABLE 200 EUROPE: MARKET, BY END USER, 2022–2032 (USD BILLION)
                        TABLE 201 EUROPE: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
             11.3.2 GERMANY
                        11.3.2.1 Improving accessibility to support market growth in Germany
                                      TABLE 202 GERMANY: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 203 GERMANY: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 204 GERMANY: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 205 GERMANY: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 206 GERMANY: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 207 GERMANY: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.3.3 UK
                        11.3.3.1 Increasing research to evaluate efficacy and potential of GLP-1 analogues to support market growth
                                      TABLE 208 UK: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 209 UK: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 210 UK: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 211 UK: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 212 UK: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 213 UK: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.3.4 FRANCE
                        11.3.4.1 Growing awareness to propel market growth
                                      TABLE 214 FRANCE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 215 FRANCE: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 216 FRANCE: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 217 FRANCE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 218 FRANCE: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 219 FRANCE: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.3.5 ITALY
                        11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market
                                      TABLE 220 ITALY: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 221 ITALY: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 222 ITALY: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 223 ITALY: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 224 ITALY: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 225 ITALY: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.3.6 SPAIN
                        11.3.6.1 Favorable initiatives for research to drive market
                                      TABLE 226 SPAIN: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 227 SPAIN: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 228 SPAIN: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 229 SPAIN: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 230 SPAIN: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 231 SPAIN: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.3.7 NETHERLANDS
                        11.3.7.1 Growing awareness and strong focus on pharmaceutical R&D to support market growth
                                      TABLE 232 NETHERLANDS: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 233 NETHERLANDS: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 234 NETHERLANDS: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 235 NETHERLANDS: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 236 NETHERLANDS: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 237 NETHERLANDS: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.3.8 REST OF EUROPE
                        TABLE 238 REST OF EUROPE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                        TABLE 239 REST OF EUROPE: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                        TABLE 240 REST OF EUROPE: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                        TABLE 241 REST OF EUROPE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                        TABLE 242 REST OF EUROPE: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                        TABLE 243 REST OF EUROPE: MARKET, BY END USER, 2022–2032 (USD BILLION)
     11.4 ASIA PACIFIC 
             11.4.1 ASIA PACIFIC: RECESSION IMPACT
                        TABLE 244 ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                        TABLE 245 ASIA PACIFIC: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                        TABLE 246 ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                        TABLE 247 ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                        TABLE 248 ASIA PACIFIC: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                        TABLE 249 ASIA PACIFIC: MARKET, BY END USER, 2022–2032 (USD BILLION)
                        TABLE 250 ASIA PACIFIC: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
             11.4.2 CHINA
                        11.4.2.1 Expansion of major biotechnology and pharmaceutical companies in China to drive market
                                      TABLE 251 CHINA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 252 CHINA: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 253 CHINA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 254 CHINA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 255 CHINA: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 256 CHINA: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.4.3 JAPAN
                        11.4.3.1 Growing availability of prominent GLP-1 drugs to drive market
                                      TABLE 257 JAPAN: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 258 JAPAN: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 259 JAPAN: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 260 JAPAN: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 261 JAPAN: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 262 JAPAN: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.4.4 INDIA
                        11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
                                      TABLE 263 INDIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 264 INDIA: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 265 INDIA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 266 INDIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 267 INDIA: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 268 INDIA: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.4.5 AUSTRALIA
                        11.4.5.1 Access to GLP-1 drugs and government support to drive market
                                      TABLE 269 AUSTRALIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 270 AUSTRALIA: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 271 AUSTRALIA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 272 AUSTRALIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 273 AUSTRALIA: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 274 AUSTRALIA: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.4.6 SOUTH KOREA
                        11.4.6.1 Collaborations in obesity drugs to propel market growth
                                      TABLE 275 SOUTH KOREA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 276 SOUTH KOREA: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 277 SOUTH KOREA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 278 SOUTH KOREA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 279 SOUTH KOREA: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 280 SOUTH KOREA: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.4.7 REST OF ASIA PACIFIC
                        TABLE 281 REST OF ASIA PACIFIC: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                        TABLE 282 REST OF ASIA PACIFIC: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                        TABLE 283 REST OF ASIA PACIFIC: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                        TABLE 284 REST OF ASIA PACIFIC: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                        TABLE 285 REST OF ASIA PACIFIC: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                        TABLE 286 REST OF ASIA PACIFIC: MARKET, BY END USER, 2022–2032 (USD BILLION)
     11.5 LATIN AMERICA 
             11.5.1 LATIN AMERICA: RECESSION IMPACT
                        TABLE 287 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                        TABLE 288 LATIN AMERICA: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                        TABLE 289 LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                        TABLE 290 LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                        TABLE 291 LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                        TABLE 292 LATIN AMERICA: MARKET, BY END USER, 2022–2032 (USD BILLION)
                        TABLE 293 LATIN AMERICA: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
             11.5.2 BRAZIL
                        11.5.2.1 Brazil to hold largest market share in Latin America
                                      TABLE 294 BRAZIL: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 295 BRAZIL: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 296 BRAZIL: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 297 BRAZIL: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 298 BRAZIL: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 299 BRAZIL: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.5.3 MEXICO
                        11.5.3.1 Growing diabetes and obesity cases to support market growth
                                      TABLE 300 MEXICO: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 301 MEXICO: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 302 MEXICO: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 303 MEXICO: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 304 MEXICO: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 305 MEXICO: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.5.4 REST OF LATIN AMERICA
                        TABLE 306 REST OF LATIN AMERICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                        TABLE 307 REST OF LATIN AMERICA: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                        TABLE 308 REST OF LATIN AMERICA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                        TABLE 309 REST OF LATIN AMERICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                        TABLE 310 REST OF LATIN AMERICA: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                        TABLE 311 REST OF LATIN AMERICA: MARKET, BY END USER, 2022–2032 (USD BILLION)
     11.6 MIDDLE EAST 
             11.6.1 MIDDLE EAST: RECESSION IMPACT
                        TABLE 312 MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                        TABLE 313 MIDDLE EAST: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                        TABLE 314 MIDDLE EAST: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                        TABLE 315 MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                        TABLE 316 MIDDLE EAST: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                        TABLE 317 MIDDLE EAST: MARKET, BY END USER, 2022–2032 (USD BILLION)
                        TABLE 318 MIDDLE EAST: MARKET, BY REGION, 2022–2032 (USD BILLION)
             11.6.2 GCC COUNTRIES
                        TABLE 319 GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                        TABLE 320 GCC COUNTRIES: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                        TABLE 321 GCC COUNTRIES: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                        TABLE 322 GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                        TABLE 323 GCC COUNTRIES: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                        TABLE 324 GCC COUNTRIES: MARKET, BY END USER, 2022–2032 (USD BILLION)
                        TABLE 325 GCC COUNTRIES: MARKET, BY COUNTRY, 2022–2032 (USD BILLION)
                        11.6.2.1 Saudi Arabia
                                     11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth
                                                     TABLE 326 SAUDI ARABIA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                                     TABLE 327 SAUDI ARABIA: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                                     TABLE 328 SAUDI ARABIA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                                     TABLE 329 SAUDI ARABIA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                                     TABLE 330 SAUDI ARABIA: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                                     TABLE 331 SAUDI ARABIA: MARKET, BY END USER, 2022–2032 (USD BILLION)
                        11.6.2.2 UAE
                                     11.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to support market growth
                                                     TABLE 332 UAE: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                                     TABLE 333 UAE: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                                     TABLE 334 UAE: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                                     TABLE 335 UAE: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                                     TABLE 336 UAE: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                                     TABLE 337 UAE: MARKET, BY END USER, 2022–2032 (USD BILLION)
                        11.6.2.3 Rest of GCC countries
                                      TABLE 338 REST OF GCC COUNTRIES: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                                      TABLE 339 REST OF GCC COUNTRIES: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                                      TABLE 340 REST OF GCC COUNTRIES: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                                      TABLE 341 REST OF GCC COUNTRIES: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                                      TABLE 342 REST OF GCC COUNTRIES: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                                      TABLE 343 REST OF GCC COUNTRIES: MARKET, BY END USER, 2022–2032 (USD BILLION)
             11.6.3 REST OF MIDDLE EAST
                        TABLE 344 REST OF MIDDLE EAST: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                        TABLE 345 REST OF MIDDLE EAST: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                        TABLE 346 REST OF MIDDLE EAST: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                        TABLE 347 REST OF MIDDLE EAST: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                        TABLE 348 REST OF MIDDLE EAST: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                        TABLE 349 REST OF MIDDLE EAST: MARKET, BY END USER, 2022–2032 (USD BILLION)
     11.7 AFRICA 
             11.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH
             11.7.2 AFRICA: RECESSION IMPACT
                        TABLE 350 AFRICA: GLP-1 ANALOGUES MARKET, BY PRODUCT, 2022–2032 (USD BILLION)
                        TABLE 351 AFRICA: MARKET, BY FORMAT, 2022–2032 (USD BILLION)
                        TABLE 352 AFRICA: MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)
                        TABLE 353 AFRICA: SUBCUTANEOUSLY ADMINISTERED GLP-1 ANALOGUES MARKET, BY TYPE, 2022–2032 (USD BILLION)
                        TABLE 354 AFRICA: MARKET, BY INDICATION, 2022–2032 (USD BILLION)
                        TABLE 355 AFRICA: MARKET, BY END USER, 2022–2032 (USD BILLION)
 
12 COMPETITIVE LANDSCAPE (Page No. - 249)
     12.1 OVERVIEW 
     12.2 KEY PLAYER STRATEGY/RIGHT TO WIN 
             12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 ANALOGUES MARKET
                        TABLE 356 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
     12.3 REVENUE ANALYSIS 
             FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN GLP-1 ANALOGUES INDUSTRY, 2021–2023
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN MARKET, 2023
             TABLE 357 GLP-1 ANALOGUES INDUSTRY: DEGREE OF COMPETITION
     12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 43 GLP-1 ANALOGUES INDUSTRY: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
     12.6 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2023 
             12.6.1 STARS
             12.6.2 EMERGING LEADERS
             12.6.3 PERVASIVE PLAYERS
             12.6.4 PARTICIPANTS
                        FIGURE 44 GLP-1 ANALOGUES MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2023
             12.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
                        12.6.5.1 Company Footprint
                                      FIGURE 45 MARKET: COMPANY FOOTPRINT (KEY PLAYERS)
                                      FIGURE 46 MARKET: COMPANY FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
                        12.6.5.2 Format footprint
                                      TABLE 358 MARKET: FORMAT FOOTPRINT
                        12.6.5.3 Route of administration footprint
                                      TABLE 359 MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
                                      TABLE 360 MARKET: ROUTE OF ADMINISTRATION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
                        12.6.5.4 Indication footprint
                                      TABLE 361 MARKET: INDICATION FOOTPRINT (KEY PLAYERS)
                                      TABLE 362 MARKET: INDICATION FOOTPRINT (PLAYERS WITH PRODUCTS IN PIPELINE)
                        12.6.5.5 Region footprint
                                      TABLE 363 GLP-1 ANALOGUES INDUSTRY: REGION FOOTPRINT (KEY PLAYERS)
     12.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 
             12.7.1 PROGRESSIVE COMPANIES
             12.7.2 RESPONSIVE COMPANIES
             12.7.3 DYNAMIC COMPANIES
             12.7.4 STARTING BLOCKS
                        FIGURE 47 MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
             12.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
                        TABLE 364 MARKET: DETAILED LIST OF KEY START-UPS/SMES
                        TABLE 365 MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
     12.8 VALUATION & FINANCIAL METRICS 
             12.8.1 FINANCIAL METRICS
                        FIGURE 48 EV/EBITDA OF KEY VENDORS
             12.8.2 COMPANY VALUATION
                        FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
     12.9 BRAND/PRODUCT COMPARISON 
             FIGURE 50 MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS (ANTIDIABETIC GLP-1 ANALOGUES)
             FIGURE 51 MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS (ANTI-OBESITY GLP-1 ANALOGUES)
     12.1 COMPETITIVE SCENARIO 
             12.10.1 PRODUCT APPROVALS
                        TABLE 366 GLP-1 ANALOGUES INDUSTRY: PRODUCT APPROVALS, JANUARY 2021–MAY 2024
             12.10.2 DEALS
                        TABLE 367 GLP-1 ANALOGUES INDUSTRY: DEALS, JANUARY 2021–MAY 2024
             12.10.3 EXPANSIONS
                        TABLE 368 GLP-1 ANALOGUES INDUSTRY: EXPANSIONS, JANUARY 2021–MAY 2024
             12.10.4 OTHER DEVELOPMENTS
                        TABLE 369 GLP-1 ANALOGUES INDUSTRY: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024
 
13 COMPANY PROFILES (Page No. - 272)
     13.1 INTRODUCTION 
(Business overview, Products offered, Recent developments & MnM View)*
     13.2 KEY PLAYERS 
             13.2.1 NOVO NORDISK A/S
                        TABLE 370 NOVO NORDISK A/S: COMPANY OVERVIEW
                        FIGURE 52 NOVO NORDISK A/S: COMPANY SNAPSHOT
                        TABLE 371 NOVO NORDISK A/S: PRODUCTS OFFERED
                        TABLE 372 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
                        TABLE 373 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2021–APRIL 2024
                        TABLE 374 NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
             13.2.2 ELI LILLY AND COMPANY
                        TABLE 375 ELI LILLY AND COMPANY: COMPANY OVERVIEW
                        FIGURE 53 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
                        TABLE 376 ELI LILLY AND COMPANY: PRODUCTS OFFERED
                        TABLE 377 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
                        TABLE 378 ELI LILLY AND COMPANY: DEALS, JANUARY 2021–APRIL 2024
                        TABLE 379 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2021–APRIL 2024
             13.2.3 SANOFI
                        TABLE 380 SANOFI: COMPANY OVERVIEW
                        FIGURE 54 SANOFI: COMPANY SNAPSHOT
                        TABLE 381 SANOFI: PRODUCTS OFFERED
             13.2.4 ASTRAZENECA
                        TABLE 382 ASTRAZENECA: COMPANY OVERVIEW
                        FIGURE 55 ASTRAZENECA: COMPANY SNAPSHOT
                        TABLE 383 ASTRAZENECA: PRODUCTS OFFERED
                        TABLE 384 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021–APRIL 2024
             13.2.5 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
                        TABLE 385 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: COMPANY OVERVIEW
                        FIGURE 56 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: COMPANY SNAPSHOT
                        TABLE 386 JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.: PRODUCTS OFFERED
             13.2.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
                        TABLE 387 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
                        FIGURE 57 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
                        TABLE 388 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS IN PIPELINE
                        TABLE 389 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2021–APRIL 2024
                        TABLE 390 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
             13.2.7 INNOVENT
                        TABLE 391 INNOVENT: COMPANY OVERVIEW
                        FIGURE 58 INNOVENT: COMPANY SNAPSHOT
                        TABLE 392 INNOVENT: PRODUCTS IN PIPELINE
                        TABLE 393 INNOVENT: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
             13.2.8 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
                        TABLE 394 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.: COMPANY OVERVIEW
                        TABLE 395 PAIGE BIOPHARMACEUTICAL (SUZHOU) CO., LTD.: PRODUCTS IN PIPELINE
             13.2.9 SCIWIND BIOSCIENCES CO., LTD.
                        TABLE 396 SCIWIND BIOSCIENCES CO., LTD.: COMPANY OVERVIEW
                        TABLE 397 SCIWIND BIOSCIENCES CO., LTD.: PRODUCTS IN PIPELINE
                        TABLE 398 SCIWIND BIOSCIENCES CO., LTD.: DEALS, JANUARY 2021–APRIL 2024
                        TABLE 399 SCIWIND BIOSCIENCES CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
             13.2.10 ZEALAND PHARMA A/S
                        TABLE 400 ZEALAND PHARMA A/S: COMPANY OVERVIEW
                        FIGURE 59 ZEALAND PHARMA A/S: COMPANY SNAPSHOT
                        TABLE 401 ZEALAND PHARMA A/S: PRODUCTS IN PIPELINE
                        TABLE 402 ZEALAND PHARMA A/S: DEALS, JANUARY 2021–APRIL 2024
                        TABLE 403 ZEALAND PHARMA A/S: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2024
             13.2.11 BEIJING DONGFANG BAITAI BIOTECHNOLOGY CO., LTD (EASTERN BIOTECH)
                        TABLE 404 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: COMPANY OVERVIEW
                        TABLE 405 BEIJING DONGFANG BAITAI BIOTECHNOLOGY: PRODUCTS IN PIPELINE
*Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
     13.3 OTHER PLAYERS 
             13.3.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
             13.3.2 VTV THERAPEUTICS
             13.3.3 TERNS PHARMACEUTICALS, INC.
             13.3.4 ALTIMMUNE
             13.3.5 SCOHIA PHARMA, INC.
             13.3.6 STRUCTURE THERAPEUTICS
             13.3.7 NEUROBO PHARMACEUTICALS, INC.
             13.3.8 I2O THERAPEUTICS, INC.
             13.3.9 AMGEN INC.
             13.3.10 PFIZER INC.
             13.3.11 MERCK & CO., INC.
             13.3.12 HANMI PHARM CO., LTD.
             13.3.13 VIKING THERAPEUTICS
             13.3.14 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
 
14 APPENDIX (Page No. - 308)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This study involved three major activities in estimating the historic, current, and forecasted size of the GLP-1 Analogues market. Exhaustive secondary research was carried out to collect information on the market, and its peer markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. A bottom-up approach was employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

The secondary sources referred to for this research study include publications from public sources, such as the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, World Obesity Federation, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, among others. Secondary sources also include business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global GLP-1 Analogue market, which was validated through primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand side of the market were interviewed to obtain qualitative and quantitative information.

GLP-1 Analogues Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

A bottom-up approach was used to estimate and validate the total size of the GLP-1 Analogues market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The list of approved GLP-1 analogues was identified through extensive secondary and primary research.  
  • The revenues generated from these GLP-1 Analogues have been determined through annual reports, and secondary sources (including paid database)
  • The products were mapped as per the segments of the market. Percentage shares, splits were determined based on the revenue contributed to each of the segments. This was verified using secondary sources and by industry experts

Global GLP-1 Analogue Market Size: Bottom-up Approach

GLP-1 Analogues Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

GLP-1 Analogues Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Glucagon-like peptide 1 (GLP-1) Analogues, alternatively termed GLP-1 receptor agonists, are drugs designed to mimic the incretin hormone glucagon-like peptide-1 (GLP-1). These drugs are primarily used for the treatment of type 2 diabetes mellitus and, more recently, obesity. They stimulate insulin secretion, inhibit glucagon release, and slow gastric emptying, which aids in lowering blood sugar levels and promotes satiety. This market is for these GLP-1 Analogues administered as a single drug or in combination with other receptor agonists, such as insulin.

Key Stakeholders

  • Pharmaceutical & biotechnology companies
  • Hospitals
  • Specialty clinics
  • Long-term care facilities
  • Academic researchers and government research organizations
  • Private research institutes
  • Contract manufacturing organizations (CMOs)
  • Contract research organizations (CROs)
  • Venture capitalists

Report Objectives

  • To define, describe, and forecast the global GLP-1 Analogues market by product, format, route of administration, indication, end user, and region
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall GLP-1 Analogue market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To provide detailed information regarding the major factors influencing the market growth, such as drivers, restraints, opportunities, and challenges
  • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
  • To strategically analyze the market structure and profile the key players of the global GLP-1 Analogues market and comprehensively analyze their core competencies2
  • To track and analyze competitive developments such as expansions, acquisitions, partnerships, collaborations, agreements, and product launches in the GLP-1 Analogues market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Geographical Analysis

  • Further breakdown of the Rest of Europe GLP-1 analogues market, by country
  • Further breakdown of the Rest of Asia Pacific GLP-1 analogues market, by country
  • Further breakdown of the Rest of Latin America GLP-1 analogues market, by country

Segment Analysis

  • Further breakdown of the therapeutic indication segment as per the product portfolio of prominent players operating in the market

Customization

  • The following customization options are available for the report:
  • Analysis on CDMO services for GLP-1 analogues and other preclinical and clinical GLP-1 analogues services
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
PH 9080
Published ON
Jul, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the GLP-1 Analogues Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback